Acer Therapeutics Inc. (ACER) Releases Quarterly Earnings Results

Acer Therapeutics Inc. (NASDAQ:ACER) released its earnings results on Monday. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, Bloomberg Earnings reports.

Shares of Acer Therapeutics (NASDAQ ACER) opened at $17.89 on Tuesday. Acer Therapeutics has a 12-month low of $5.18 and a 12-month high of $22.63.

Separately, ValuEngine cut shares of Acer Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 2nd.

COPYRIGHT VIOLATION WARNING: “Acer Therapeutics Inc. (ACER) Releases Quarterly Earnings Results” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another publication, it was copied illegally and republished in violation of international trademark and copyright law. The original version of this article can be read at https://sportsperspectives.com/2017/11/14/acer-therapeutics-inc-acer-releases-quarterly-earnings-results.html.

Acer Therapeutics Company Profile

Acer Therapeutics Inc, formerly Opexa Therapeutics, Inc, is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001.

Earnings History for Acer Therapeutics (NASDAQ:ACER)

Receive News & Ratings for Acer Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acer Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply